Metraipolis › archive › dc_d52ce66d0367
Continuation of atezolizumab plus bevacizumab beyond initial progressive disease: clinical benefits in patients with unresectable hepatocellular carcinoma - a… — Europe PMC PMID:41019089
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41019089
- DOI
- 10.3389/fimmu.2025.1653456
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T00:32:51.455Z
- SHA-256 of the archived text
63e1a0d2102152a8e701dd968afa3bb1f988e752609a48ab57a72110eea44520- Stable URL of this page
https://metraipolis.com/documento/dc_d52ce66d0367
How to cite
Continuation of atezolizumab plus bevacizumab beyond initial progressive disease: clinical benefits in patients with unresectable hepatocellular carcinoma - a… — Europe PMC PMID:41019089 — Europe PMC (en), https://europepmc.org/article/MED/41019089 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d52ce66d0367 (Metraipolis archive dc_d52ce66d0367, sha256 63e1a0d2102152a8e701dd968afa3bb1f988e752609a48ab57a72110eea44520)
BibTeX
@misc{dcd52ce66d0367,
title = {Continuation of atezolizumab plus bevacizumab beyond initial progressive disease: clinical benefits in patients with unresectable hepatocellular carcinoma - a… — Europe PMC PMID:41019089},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41019089},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d52ce66d0367; sha256 63e1a0d2102152a8e701dd968afa3bb1f988e752609a48ab57a72110eea44520},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41019089. Agents can read the archived copy with the MCP tool read_document.